Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
T Gantke, M Weichel, C Herbrecht… - Protein Engineering …, 2017 - academic.oup.com
Bispecific antibodies that redirect the lytic activity of cytotoxic immune effector cells, such as
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
T Gantke, M Weichel, C Herbrecht… - … , Design & Selection, 2017 - search.ebscohost.com
Bispecific antibodies that redirect the lytic activity of cytotoxic immune effector cells, such as
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
T Gantke, M Weichel, C Herbrecht… - … , Design & Selection …, 2017 - europepmc.org
Bispecific antibodies that redirect the lytic activity of cytotoxic immune effector cells, such as
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
[PDF][PDF] Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
T Gantke, M Weichel, C Herbrecht… - … , Design & Selection, 2017 - researchgate.net
Bispecific antibodies that redirect the lytic activity of cytotoxic immune effector cells, such as
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
T Gantke, M Weichel, C Herbrecht… - Protein Engineering …, 2017 - academic.oup.com
Bispecific antibodies that redirect the lytic activity of cytotoxic immune effector cells, such as
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
T Gantke, M Weichel, C Herbrecht… - … design & selection …, 2017 - pubmed.ncbi.nlm.nih.gov
Bispecific antibodies that redirect the lytic activity of cytotoxic immune effector cells, such as
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …
T-and NK cells, onto tumor cells have emerged as a highly attractive and clinically validated …